What changed: Diffuse large B-cell lymphoma
Every dated change on the records linked to Diffuse large B-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 5
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Advanced stage, IPI 0-1
R-CHOP × 6 (or Pola-R-CHP); consider 4 cycles plus 2 rituximab in young low-risk patients (FLYER). (NCCN Category 1)
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Advanced stage, IPI 2-5
Pola-R-CHP × 6 (POLARIX) or R-CHOP × 6; tafasitamab + lenalidomide + R-CHOP (frontMIND) pending approval for IPI 3-5; DA-EPOCH-R for double-hit lymphoma; CNS prophylaxis for high CNS-IPI (contested). (NCCN Pola-R-CHP category 1 for IPI 2-5)
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN 2026: Primary refractory or relapse within 12 months
CD19 CAR-T (axi-cel or liso-cel) preferred over salvage chemotherapy and transplant (ZUMA-7, TRANSFORM); bridging therapy while manufacturing; bispecific ± chemotherapy if CAR-T unavailable. (NCCN Category 1 (axi-cel, liso-cel))
- 2026GuidelineDiffuse large B-cell lymphomaGuideline NCCN B-Cell Lymphomas 2026: Limited stage (I-II, non-bulky)
R-CHOP × 4 with PET-guided omission of radiation (FLYER, S1001): 4 cycles if interim PET negative; involved-site radiotherapy if PET positive. (NCCN Category 1 (R-CHOP × 4 PET-adapted for stage I-II))
- 2026MilestoneDiffuse large B-cell lymphomafrontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA
A milestone in how this cancer is treated.
2025 · 1
2024 · 1
2023 · 2
2022 · 2
2021 · 1
2020 · 1
2019 · 1
2017 · 2
2014 · 1
2010 · 1
2002 · 1
2000 · 1
1997 · 3
- 1997ApprovalRituximabRituximab approved in US
Relapsed follicular lymphoma; first antibody approved for cancer
- 1997MilestoneDiffuse large B-cell lymphomaRituximab: first antibody for cancer
A milestone in how this cancer is treated.
- 1997MilestoneCD20Rituximab: first monoclonal antibody approved for cancer
A milestone in how this cancer is treated.